Adsorption- and Displacement-Based Approaches for the Removal of Protein-Bound Uremic Toxins

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2023 Feb 24

PMID 36828424

Authors

Flavia S C Rodrigues

Monica Faria

Affiliations

Soon will be listed here.

Abstract

End-stage renal disease (ESRD) patients rely on renal replacement therapies to survive. Hemodialysis (HD), the most widely applied treatment, is responsible for the removal of excess fluid and uremic toxins (UTs) from blood, particularly those with low molecular weight (MW < 500 Da). The development of high-flux membranes and more efficient treatment modes, such as hemodiafiltration, have resulted in improved removal rates of UTs in the middle molecular weight range. However, the concentrations of protein-bound uremic toxins (PBUTs) remain essentially untouched. Due to the high binding affinity to large proteins, such as albumin, PBUTs form large complexes (MW > 66 kDa) which are not removed during HD and their accumulation has been strongly associated with the increased morbidity and mortality of patients with ESRD. In this review, we describe adsorption- and displacement-based approaches currently being studied to enhance the removal of PBUTs. The development of mixed matrix membranes (MMMs) with selective adsorption properties, infusion of compounds capable of displacing UTs from their binding site on albumin, and competitive binding membranes show promising results, but the road to clinical application is still long, and further investigation is required.

Citing Articles

The Choice of Anti-Inflammatory Influences the Elimination of Protein-Bound Uremic Toxins.

Escudero-Saiz V, Cuadrado-Payan E, Rodriguez-Garcia M, Casals G, Rodas L, Fontsere N Toxins (Basel). 2024; 16(12).

PMID: 39728803 PMC: 11679929. DOI: 10.3390/toxins16120545.

Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.

Shi L, Wang J, Wei T, Liang Z, Zhang L, Li C Int Urol Nephrol. 2024; .

PMID: 39589637 DOI: 10.1007/s11255-024-04290-4.

Displacing the Burden: A Review of Protein-Bound Uremic Toxin Clearance Strategies in Chronic Kidney Disease.

Sanchez-Ospina D, Mas-Fontao S, Gracia-Iguacel C, Avello A, Gonzalez de Rivera M, Mujika-Marticorena M J Clin Med. 2024; 13(5).

PMID: 38592263 PMC: 10934686. DOI: 10.3390/jcm13051428.

Focus on Mitochondrial Respiratory Chain: Potential Therapeutic Target for Chronic Renal Failure.

Wang Y, Yang J, Zhang Y, Zhou J Int J Mol Sci. 2024; 25(2).

PMID: 38256023 PMC: 10815764. DOI: 10.3390/ijms25020949.

Improving Structural Homogeneity, Hydraulic Permeability, and Mechanical Performance of Asymmetric Monophasic Cellulose Acetate/Silica Membranes: Spinodal Decomposition Mix.

Zare F, Goncalves S, Faria M, Goncalves M Membranes (Basel). 2023; 13(3).

PMID: 36984734 PMC: 10059883. DOI: 10.3390/membranes13030346.

References

Ficheux A, Kerr P, Brunet P, Argiles A . The ultrafiltration coefficient of a dialyser (KUF) is not a fixed value, and it follows a parabolic function: the new concept of KUF max. Nephrol Dial Transplant. 2010; 26(2):636-40. DOI: 10.1093/ndt/gfq510. View

Tao X, Thijssen S, Levin N, Kotanko P, Handelman G . Enhanced Indoxyl Sulfate Dialyzer Clearance with the Use of Binding Competitors. Blood Purif. 2015; 39(4):323-30. DOI: 10.1159/000381008. View

Maduell F . Hemodiafiltration versus conventional hemodialysis: Should "conventional" be redefined?. Semin Dial. 2018; 31(6):625-632. DOI: 10.1111/sdi.12715. View

Fasano M, Curry S, Terreno E, Galliano M, Fanali G, Narciso P . The extraordinary ligand binding properties of human serum albumin. IUBMB Life. 2006; 57(12):787-96. DOI: 10.1080/15216540500404093. View

Ronco C, Brendolan A, Crepaldi C, Rodighiero M, Scabardi M . Blood and dialysate flow distributions in hollow-fiber hemodialyzers analyzed by computerized helical scanning technique. J Am Soc Nephrol. 2002; 13 Suppl 1:S53-61. View

Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T . Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem. 2012; 403(7):1841-50. DOI: 10.1007/s00216-012-5929-3. View

Zhang Z, Yang T, Li Y, Li J, Yang Q, Wang L . Effects of Expanded Hemodialysis with Medium Cut-Off Membranes on Maintenance Hemodialysis Patients: A Review. Membranes (Basel). 2022; 12(3). PMC: 8953230. DOI: 10.3390/membranes12030253. View

Hung Y, Lai T, Belmouaz M, Tu Y, Lai C, Lin S . Effects of Medium Cut-Off Polyarylethersulfone and Polyvinylpyrrolidone Blend Membrane Dialyzers in Hemodialysis Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Membranes (Basel). 2022; 12(5). PMC: 9144787. DOI: 10.3390/membranes12050443. View

Vanholder R, van Laecke S, Glorieux G . What is new in uremic toxicity?. Pediatr Nephrol. 2008; 23(8):1211-21. PMC: 2441592. DOI: 10.1007/s00467-008-0762-9. View

10.

Chen J, Chiang C . Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence. Toxins (Basel). 2022; 14(1). PMC: 8780792. DOI: 10.3390/toxins14010008. View

11.

Ronco C, Clark W . Haemodialysis membranes. Nat Rev Nephrol. 2018; 14(6):394-410. DOI: 10.1038/s41581-018-0002-x. View

12.

Tao X, Thijssen S, Kotanko P, Ho C, Henrie M, Stroup E . Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an in vitro human whole blood study. Sci Rep. 2016; 6:23389. PMC: 4802219. DOI: 10.1038/srep23389. View

13.

Leong S, Sao J, Taussig A, Plummer N, Meyer T, Sirich T . Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis. J Am Soc Nephrol. 2018; 29(7):1992-1999. PMC: 6050930. DOI: 10.1681/ASN.2018010081. View

14.

Sundstrom J, Bodegard J, Bollmann A, Vervloet M, Mark P, Karasik A . Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur. 2022; 20:100438. PMC: 9459126. DOI: 10.1016/j.lanepe.2022.100438. View

15.

Zhu J, Yi X, Huang P, Chen S, Wu Y . Drug-protein binding of Danhong injection and the potential influence of drug combination with aspirin: Insight by ultrafiltration LC-MS and molecular modeling. J Pharm Biomed Anal. 2016; 134:100-107. DOI: 10.1016/j.jpba.2016.11.028. View

16.

Pavlenko D, van Geffen E, van Steenbergen M, Glorieux G, Vanholder R, Gerritsen K . New low-flux mixed matrix membranes that offer superior removal of protein-bound toxins from human plasma. Sci Rep. 2016; 6:34429. PMC: 5050520. DOI: 10.1038/srep34429. View

17.

Lekawanvijit S . Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome. Toxins (Basel). 2018; 10(9). PMC: 6162485. DOI: 10.3390/toxins10090352. View

18.

Lu L, Chen C, Samarasekera C, Yeow J . Influence of zeolite shape and particle size on their capacity to adsorb uremic toxin as powders and as fillers in membranes. J Biomed Mater Res B Appl Biomater. 2016; 105(6):1594-1601. DOI: 10.1002/jbm.b.33698. View

19.

de Loor H, Meijers B, Meyer T, Bammens B, Verbeke K, Dehaen W . Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A. 2009; 1216(22):4684-8. DOI: 10.1016/j.chroma.2009.04.015. View

20.

Tang Y, Tsai Y, Chen T, Li S . Artificial Kidney Engineering: The Development of Dialysis Membranes for Blood Purification. Membranes (Basel). 2022; 12(2). PMC: 8876607. DOI: 10.3390/membranes12020177. View